Published February 28, 2026
| Version v1
Book chapter
Open
AI-Driven Nanomedicine for Targeted Drug Delivery
Authors/Creators
- 1. Assistant Professor, Department of Botany, SIES College of Arts, Science and Commerce (Empowered Autonomous), Sion (W)
Description
Nanomedicine has emerged as a transformative platform for precision therapeutics, offering the ability to engineer nanoparticles that selectively deliver drugs to disease sites while minimizing systemic toxicity. Recent advances in targeted drug delivery systems—including liposomes, polymeric nanoparticles, dendrimers, and lipid-based carriers have improved efficacy and safety profiles in oncology, infectious diseases, and chronic conditions. The integration of Artificial Intelligence (AI) into nanomedicine design, formulation optimization, and clinical translation represents a paradigm shift. Machine learning and predictive modeling facilitate rational nanocarrier design, anticipate biological interactions such as protein corona formation, optimize drug loading and release kinetics, and enable patient-specific therapeutic strategies. AI-driven approaches accelerate pre-clinical development, enhance precision medicine, and support regulatory decision-making. This chapter provides a comprehensive overview of nanocarrier platforms, passive and active targeting mechanisms, stimuli-responsive systems, and highlights the emerging role of AI in shaping the future of intelligent, personalized drug delivery.
Files
8. Ms. Ruchika Amish Yadav.pdf
Files
(515.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3a5caa29f6f93e69a8ec4799cc6278af
|
515.9 kB | Preview Download |
Additional details
References
- 1. Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), 505–515. https://doi.org/10.1021/mp800051m 2. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037 3. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. Bioengineering & Translational Medicine, 4(3), e10143. https://doi.org/10.1002/btm2.10143 4. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020 5. Beldman, T. J., Malinova, T. S., Desclos, E., et al. (2017). Nanoparticle-aided characterization of arterial endothelial architecture during atherosclerosis progression and metabolic therapy. ACS Nano, 11(6), 5785–5799. https://doi.org/10.1021/acsnano.7b01933 6. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. https://doi.org/10.1038/nbt.3330 7. Champion, J. A., & Mitragotri, S. (2006). Role of target geometry in phagocytosis. Proceedings of the National Academy of Sciences, 103(13), 4930–4934. https://doi.org/10.1073/pnas.0600997103 8. Danhier, F. (2016). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 244, 108–121. https://doi.org/10.1016/j.jconrel.2016.07.036 9. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522. https://doi.org/10.1016/j.jconrel.2012.01.043 10. Etheridge, M. L., Campbell, S. A., Erdman, A. G., et al. (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine, 9(1), 1–14. https://doi.org/10.1016/j.nano.2012.05.013 11. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16–20. https://doi.org/10.1021/nn900002m 12. Huang, X., Zhang, F., Wang, H., et al. (2020). Targeted nanoparticles for cancer therapy: Advances and perspectives. Nanomedicine, 15(6), 567–586. https://doi.org/10.2217/nnm-2019-0326 13. Kesharwani, P., Jain, K., & Jain, N. K. (2015). Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science, 39(2), 268–307. https://doi.org/10.1016/j.progpolymsci.2013.07.005 14. Liu, J., Huang, Y., Kumar, A., et al. (2014). Stimuli-responsive nanocarriers for drug delivery. Nature Reviews Materials, 1(1), 16002. https://doi.org/10.1038/natrevmats.2016.2 15. Longmire, M., Choyke, P. L., & Kobayashi, H. (2008). Clearance properties of nano-sized particles and molecules as imaging agents. Nanomedicine, 3(5), 703–717. https://doi.org/10.2217/17435889.3.5.703 16. Maeda, H., Nakamura, H., & Fang, J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering systemic toxicity. Journal of Controlled Release, 164(2), 138–144. https://doi.org/10.1016/j.jconrel.2012.10.002 17. Mi, P. (2020). Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics, 10(10), 4557-4588. https://doi.org/10.7150/thno.38069. 18. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals. Nature Reviews Drug Discovery, 13(9), 655–672. https://doi.org/10.1038/nrd4363 19. Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005). Nanomedicine: Current status and future prospects. FASEB Journal, 19(3), 311–330. https://doi.org/10.1096/fj.04-2747rev 20. Muro, S. (2012). Challenges in design and characterization of ligand-targeted drug delivery systems. 21. Journal of Controlled Release, 164(2), 125–137. https://doi.org/10.1016/j.jconrel.2012.04.017 22. Peer, D., Karp, J. M., Hong, S., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. 23. Nature Nanotechnology, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387 24. Saraiva, C., Praça, C., Ferreira, R., et al. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. Journal of Controlled Release, 235, 34–47. https://doi.org/10.1016/j.jconrel.2016.05.044 25. Sharma, A., et al. (2020). Lipid-based nanocarriers for drug delivery: A review. Journal of Drug Delivery Science and Technology, 59, 101875. https://doi.org/10.1016/j.jddst.2020.101875 26. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108 27. Suk, J. S., Xu, Q., Kim, N., et al. (2016). PEGylation as a strategy for improving nanoparticle-based drug delivery. Advanced Drug Delivery Reviews, 99, 28–51. https://doi.org/10.1016/j.addr.2015.09.012 28. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. 29. Nature Reviews Drug Discovery, 13(11), 813–827. https://doi.org/10.1038/nrd4333 30. Veronese, F. M., & Pasut, G. (2005). PEGylation, successful approach to drug delivery. Drug Discovery Today, 10(21), 1451–1458. https://doi.org/10.1016/S1359-6446(05)03575-0 31. Wilhelm, S., Tavares, A. J., Dai, Q., et al. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1, 16014. https://doi.org/10.1038/natrevmats.2016.14